This article has an addendum: Patient consent was required and obtained.
Original article: Oncotarget. 2018; 9:33043–33049. 33043-33049. https://doi.org/10.18632/oncotarget.25984
. 2023 Jul 1;14:668. doi: 10.18632/oncotarget.28471
Addendum: Immune-related adverse events and atypical radiological response with checkpoint inhibitor immunotherapy in an elderly patient with high PD-L1 expressing lung adenocarcinoma
Eduard Teixidor
1, Elia Sais
1, Carmen Amalia Vásquez
2, Walter Carbajal
1, Alejandro Hernández
1, Gloria Sánchez
3, Angel Izquierdo
1, Sara Verdura
4,5, Javier A Menéndez
4,5, Joaquim Bosch-Barrera
1,5,6,✉
Eduard Teixidor
1Department of Medical Oncology, Catalan Institute of Oncology, Doctor Josep Trueta University Hospital, Girona, Spain
Find articles by Eduard Teixidor
Elia Sais
1Department of Medical Oncology, Catalan Institute of Oncology, Doctor Josep Trueta University Hospital, Girona, Spain
Find articles by Elia Sais
Carmen Amalia Vásquez
2Department of Anatomical Pathology, Dr. Josep Trueta Hospital of Girona, Girona, Catalonia, Spain
Find articles by Carmen Amalia Vásquez
Walter Carbajal
1Department of Medical Oncology, Catalan Institute of Oncology, Doctor Josep Trueta University Hospital, Girona, Spain
Find articles by Walter Carbajal
Alejandro Hernández
1Department of Medical Oncology, Catalan Institute of Oncology, Doctor Josep Trueta University Hospital, Girona, Spain
Find articles by Alejandro Hernández
Gloria Sánchez
3Department of Radiology, Diagnostic Imaging Institute, Doctor Josep Trueta University Hospital, Girona, Spain
Find articles by Gloria Sánchez
Angel Izquierdo
1Department of Medical Oncology, Catalan Institute of Oncology, Doctor Josep Trueta University Hospital, Girona, Spain
Find articles by Angel Izquierdo
Sara Verdura
4ProCURE (Program Against Cancer Therapeutic Resistance), Metabolism and Cancer Group, Catalan Institute of Oncology, Girona, Catalonia, Spain
5Girona Biomedical Research Institute (IDIBGi), Girona, Catalonia, Spain
Find articles by Sara Verdura
Javier A Menéndez
4ProCURE (Program Against Cancer Therapeutic Resistance), Metabolism and Cancer Group, Catalan Institute of Oncology, Girona, Catalonia, Spain
5Girona Biomedical Research Institute (IDIBGi), Girona, Catalonia, Spain
Find articles by Javier A Menéndez
Joaquim Bosch-Barrera
1Department of Medical Oncology, Catalan Institute of Oncology, Doctor Josep Trueta University Hospital, Girona, Spain
5Girona Biomedical Research Institute (IDIBGi), Girona, Catalonia, Spain
6Department of Medical Sciences, Medical School, University of Girona, Girona, Spain
Find articles by Joaquim Bosch-Barrera
1Department of Medical Oncology, Catalan Institute of Oncology, Doctor Josep Trueta University Hospital, Girona, Spain
2Department of Anatomical Pathology, Dr. Josep Trueta Hospital of Girona, Girona, Catalonia, Spain
3Department of Radiology, Diagnostic Imaging Institute, Doctor Josep Trueta University Hospital, Girona, Spain
4ProCURE (Program Against Cancer Therapeutic Resistance), Metabolism and Cancer Group, Catalan Institute of Oncology, Girona, Catalonia, Spain
5Girona Biomedical Research Institute (IDIBGi), Girona, Catalonia, Spain
6Department of Medical Sciences, Medical School, University of Girona, Girona, Spain
✉
Correspondence to: Joaquim Bosch-Barrera, email : jbosch@iconcologia.net
Collection date 2023.
Copyright: © 2023 Teixidor et al.
This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
PMCID: PMC10317036 PMID: 37395727